Michael S. Abrams - 28 Jul 2026 Form 4 Insider Report for NRX Pharmaceuticals, Inc. (NRXP)

Reporting relationship: Chief Financial Officer
Issuer ticker: NRXP
Reported as of: 28 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Nov 2026, 17:52:06 UTC
Prior SEC filing: 11 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Michael Abrams

Filing notes and source

Key filing fact

Michael S. Abrams filed Form 4 for NRX Pharmaceuticals, Inc. (NRXP) on 04 Nov 2026.

Key facts

This page summarizes Michael S. Abrams's Form 4 filing for NRX Pharmaceuticals, Inc. (NRXP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Nov 2026, 17:52.

Change

Previous filing in this sequence was filed on 11 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001497702 Primary reporting owner

ABRAMS MICHAEL S

Relationship: Chief Financial Officer
Address: C/O NRX PHARMACEUTICALS, INC., 1201 ORANGE STREET, SUITE 600, WILMINGTON
Signature: /s/ Michael Abrams
Signature date: 04 Nov 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NRXP transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +75,000
Change %
Price: $0.000000^*
Shares after: 75,000
Date: 28 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 75,000
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit ("RSUs') represents a contingent right to receive one share of the Issuer's common stock at the time of vesting for no consideration.

Footnote F2

The restricted stock units were granted under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan, as amended. The RSUs vest in three equal annual installments on July 28, 2027, July 28, 2028 and July 28, 2029, subject to the reporting person's continued service through each vesting date.